FeesSafety
Pluang+

Ziphius appoints vaccine veteran Antoon Loomans to board to boost strategic growth and funding.

Company Fundamentals
17 Nov 2026, 06:54 WIB
Na
View Source
Bullish
Ziphius appoints vaccine veteran Antoon Loomans to board to boost strategic growth and funding.

Ziphius, a biotech firm specializing in self-amplifying RNA vaccines, has appointed Antoon Loomans to its board of directors to lead U.S. business development and strategic partnerships. Loomans brings 30 years of vaccine industry experience, including senior roles at GSK and VaxCo. This move supports Ziphius' advancement of its flagship Chlamydia vaccine program towards clinical trials and a €30 million fundraising effort to finance product development through Phase I trials. Loomans aims to leverage his expertise to secure partnerships and funding to maximize the platform's potential for patients and shareholders.

GSK shares trade at USD 50.41 on Pluang as of Nov 17, 2026 07:02 WIB, down slightly by 0.08% in one day. The company holds a market cap of $101.39 billion and offers a dividend yield of 3.64%. This stable performance occurs while Ziphius appoints Antoon Loomans to boost its vaccine development efforts, potentially impacting related biotech sectors.

More News (GSK)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App